Alvogen has an office in Taipei, with four employees. The office is lead by Siegfried Gschliesser, Regional Directory for North Asia. Alvogen’s approach in Taiwan is to register new products on the market, starting with a portfolio of high quality cosmetics in the Women/ Children and Gastro health range, and gradually build up product offering, through partnerships and possible portfolio acquisitions.
The Taiwan pharmaceutical market is very competitive with high volume growth, recent changes in implementing stricter quality standards and a push by the National Health Insurance to reduce cost will lead to many changes in the market.
Some USD 1.6 bn. are currently being generated by the sale of patented Originator products and this market segment is expected to turn generic within the next few years. These changes will open up lots of opportunities for fast moving, decisive companies with large portfolios of high quality products and strong pipelines. "Alvogen Taiwan is very well positioned to capture these opportunities and we are looking forward to a rapid increase in market share and revenue growth", says Siegfried Gschliesser, Regional Director Taiwan.